A Comparative, Randomized, Double blind, Multicentric, Clinical Study to Evaluate the Efficacy, Safety and Tolerability of Besifloxacin ophthalmic suspension 0.6% Vs Moxifloxacin ophthalmic solution 0.5% in patients with Bacterial conjunctivitis.
Latest Information Update: 14 Dec 2018
At a glance
- Drugs Besifloxacin (Primary) ; Moxifloxacin
- Indications Bacterial conjunctivitis; Infectious conjunctivitis
- Focus Therapeutic Use
- Sponsors Ajanta Pharma
- 04 Sep 2010 Status changed from active, no longer recruiting to completed as reported by Clinical Trials Registry - India record.
- 11 Aug 2010 Status changed from not yet recruiting to active, no longer recruiting as reported by Clinical Trials Registry - India record.
- 14 Apr 2010 Planned initiation date changed from 12 Apr 2010 to 26 Apr 2010 as reported by Clinical Trials Registry - India record.